ClinicalTrials.gg
RecruitingNCT06607055IMMUNAIXUpdated Aug 26, 2026

Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia

An observational study in Pneumonia, Ventilator-Associated, sponsored by Centre Hospitalier Intercommunal Aix-Pertuis. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by Centre Hospitalier Intercommunal Aix-Pertuis · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Planned enrollment
29th of 33
40 · median 268
Started
2023
with 7 others
Observational
33 of 80
9 open now
Primary completion
2026-12
later than 9 of 21 live
Registered
69th of 80
by date
Lead sponsor
2 of 80
Centre Hospitalier Intercommunal Aix-Pertuis

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 29th largest by planned enrollment of the 33 observational ones that give a count, is one of 8 that started in 2023, is one of 33 observational ones, reaches primary completion later than 9 of the 21 other live ones, and was the 69th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit.

The main questions it aims to answer are:

  • evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring
  • search an association between immunoplegia depth and severity of the initial state of shock
  • search an association between immunoplegia depth and viral reactivation
  • compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.
Read the detailed description

The occurrence of ICU-acquired infections in patients admitted to the intensive care unit (ICU) results in increased morbidity and mortality, increased length of stay in the ICU, and also clearly increased healthcare costs. The incidence of these infections fluctuates between 15% and 40%, depending on the study. A major problem in the ICU is the recurrence and relapse of ventilator-associated pneumonia (VAP), with increased exposure to antibiotics and a probable increase in average length of stay.

One of the possible hypothesis that could explain relapses/recurrences of VAP is incorrect conducted antibiotherapy. To prevent this, in the unit, we currently perform antibiotics pharmacological assays and adapt them to the antibiogram. Another possible explanation to treatment failure could be patients' postagressive immunoparalysis. It has clearly been demonstrated that postagressive immunoparalysis is a predisposing state to healthcare related infections.

Some markers can be used to monitor this immunoplegia state. Several studies have shown that low HLA-DR expression and reduced CD16 expression (polymorphonuclear neutrophils percentage) is associated with increased susceptibility to develop infections in the ICU.

Immunity monitoring could be an interesting tool to identify populations most at risk of developing healthcare-associated infections after a state of shock, and could become an interesting line of thinking for the use of immunomodulatory therapies. To best evaluate these therapies and find a place for them in the current arsenal, it is essential to integrate them into daily practice by linking them to a significant clinical event, such as recurrent healthcare-associated infections, despite properly conducted antibiotic treatment.

03

Conditions studied

  • Pneumonia, Ventilator-Associated
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient admitted in the ICU of the CHIAP under mechanical ventilation and with infectious pneumonia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient over 18 years old
  • Patient admitted in the Intensive Care Unit of the CHIAP
  • Patient under mechanical ventilation
  • Patient with infectious pneumonia
  • Form (ICF) obtained from the patient or emergency ICF obtained from close relatives
  • Patient beneficiary of French social security, whatever the regime

Exclusion criteria

Exclusion Criteria:

  • Patient under 18 years old
  • Patient with severe neutropenia (neutrophils \< 0.5 G/L)
  • Patient under treatment
  • Use of (intravenous or oral) prior to ICU admission
  • Use of therapeutic antibodies
  • Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion
  • End of chemotherapy 6 months prior to inclusion
  • Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, or AIDS, at any stage)
  • Patients with a decision to limit or discontinue active therapies, at the time of inclusion
  • Patients with an estimated ICU stay of less than 48 hours
  • Participation in an interventional study
  • Patient deprived of their liberty
  • Patient under tutorship or curatorship
  • Pregnant or breastfeeding woman
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Interventional - blood collection

    HLA-DR dosage, at the time of inclusion and once a week then

    Diagnostic Test: Blood collection

Interventions

  • Diagnostic testBlood collection

    HLA-DR dosage, at the time of inclusion and once a week then

06

What researchers measure

Primary outcomes

  1. Occurrence of a VAP recurrence/relapse

    Number of occurrence of a VAP recurrence/relapse

    Time frame: From date of hospital admission until the date of the end of hospitalization or date of death from any cause, whichever came first, assessed up to 100 months

Secondary outcomes

  1. Viral reactivation

    To search for association between immunoplegia depth and viral reactivation (CMV)

    Time frame: From date of hospital admission until the date of the end of hospitalization or date of death from any cause, whichever came first, assessed up to 100 months

  2. Association between immunoparalysis depth and state of shock severity within the first 24 hours

    To search for association between immunoplegia depth and severity of the initial state of shock (lactatemia, amine dosage, SOFA score over 48 hours)

    Time frame: First 24 hours

  3. Persistence of immunoparalysis during hospitalization and care-related infections

    To compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence

    Time frame: From date of hospital admission until the date of the end of hospitalization or date of death from any cause, whichever came first, assessed up to 100 months

  4. HLA-DR nadir and link with care-related infections

    To compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence

    Time frame: From date of hospital admission until the date of the end of hospitalization or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 63 non-industry observational studies under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 38 months is above that.

Counting every sponsor, half of 63 studies reached it within 20 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Sep 23, 2024
StartActual
Oct 4, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06607055
Lead sponsor
Centre Hospitalier Intercommunal Aix-Pertuis
Responsible party
Laurent LEFEBVRE (Principal investigator, Centre Hospitalier Intercommunal Aix-Pertuis) — Principal investigator
First posted
Sep 23, 2024
Start date
Oct 4, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Aug 26, 2026

Study contacts

Laurent LEFEBVRE, MD
Contact
llefebvre@ch-aix.fr
0442335650 ext. +33
Laurent LEFEBVRE, MD
principal investigator · Centre Hospitalier Intercommunal Aix-Pertuis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion